LiDCO Group Plc 19 January 2006 Immediate Release 19 January 2006 LiDCO GROUP PLC (LiDCO or "The Company") LIDCOplus MONITOR DEVELOPMENT REDUCES NEED FOR INVASIVE CATHETERS LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, is pleased to announce that it will be increasing the scope of its product by the introduction of a new measurement, namely the intrathoracic blood volume (ITBV). Accurately measuring the volume of blood in the thorax could be of significant benefit to patients and should widen the attraction of its system to doctors working in intensive care. Importantly, this development will take away the need to insert an invasive catheter into the central venous system, and heart or major artery, which is the currently established technique for taking the measurements. The ITBV measurement will be introduced in the second quarter of 2006. The lithium ion injection is currently used by LiDCO as a marker substance to measure cardiac output. Combining this existing measurement with the time taken for the lithium marker to transit from the injection point to the LiDCO sensor provides a new measurement - the ITBV. Physicians endeavour to increase the thoracic blood volume in order to rehydrate patients in surgery, trauma and intensive care locations. Correct fluid management improves cardiac performance and critically the oxygen delivery to vital organs that has been shown to reduce hospital bed stay. The ITBV is a much more sensitive guide to the fluid management of patients than the traditional invasive catheter based measurement of pulmonary artery wedge pressure. LiDCO expects that this new measurement will have widespread application in the improved fluid management of patients. Dr Terry O'Brien, Chief Executive of LiDCO, stated: "The lithium ion based measurement of ITBV significantly augments the utility of the LiDCOplus Monitor. I believe this parameter will prove to be highly useful in the management of cardiac performance to optimize oxygen delivery in patients requiring fluid replacement. This should substantially increase the market potential for use of our patent protected lithium based technology." For further information please contact: LiDCO Group Plc Terry O'Brien - Chief Executive Hugh McGarel-Groves - Finance Director Tel: +44 (0)20 7749 1500 Buchanan Communications Tim Anderson, James Strong Tel: +44 (0)20 7466 5000 Panmure Gordon Grant Harrison, Aubrey Powell, Katherine Roe Tel: +44 (0)20 7459 3600 Notes to Editors About LiDCO Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO's technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London where the Company maintains a research base. The Company's manufacturing facility is in Hoxton, London and its current products are: • LiDCOplus and PulseCO monitors: computer-based platforms for displaying a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume; • LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner. Distribution Network: The Company has now achieved registration of its products in 13 markets in Europe, the USA, Brazil and Japan. It sells direct to the NHS in the UK, and through a worldwide network of specialty critical care distributors. Background to the recently published clinical trial: Better than standard care - (EGDT) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO's minimally invasive monitoring technology were presented during the 25th International Symposium on Intensive Care and Emergency Medicine in Brussels (21st to 25th March 2005). The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000 per patient. Extrapolated nationally, this would equate to a saving of £500 million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62 patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significant reduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissue oxygen levels following surgery. This information is provided by RNS The company news service from the London Stock Exchange